Impax completes enrollment for late-stage trial for Parkinson’s disease drug
HAYWARD, Calif. The brand drugs division of Impax Labs has finished enrolling patients in a late-stage clinical trial of a drug for Parkinson’s disease, Impax announced Thursday.
Impax Pharmaceuticals said the APEX-PD trial is a multinational phase 3 trial of the drug IPX066 (carbidopa, levodopa), for subjects with early Parkinson’s.
“We are very pleased to have completed enrollment in APEX-PD, meeting an important milestone for IPX066 and for Impax Pharmaceuticals as we plan for potential product launch,” Impax Pharmaceuticals president Michael Nestor said. “We look forward to revealing the top-line results for this trial in early 2011.”
FMI praises Brown’s Super Markets president’s commitment to consumers
ARLINGTON, Va. An organization representing food retailers and wholesalers praised one grocery chain head’s commitment to improving the availability of nutritious food for its consumers.
The Food Marketing Institute that testimony presented before the House Agriculture Subcommittee on Department Operations, Oversight, Nutrition, and Forestry by Jeff Brown, president and owner of Brown’s Super Markets, shows how partnerships with federal and community leaders “can overcome the challenges inherent in building stores in underserved areas.”
“Food Marketing Institute applauds Jeff Brown for sharing his vision and success in bringing fresh, affordable and nutritious food to low-income Americans in areas that lack ready access to supermarkets, said Leslie Sarasin, FMI president and CEO. “Retail food stores are the cornerstone of communities nationwide, creating numerous jobs and serving as catalyst for economic growth.”
Pfizer Oncology to present cancer drugs at annual cancer research conference
NEW YORK Presenters from Pfizer’s cancer drugs unit will have a lot of work to do at the annual meeting of the American Association for Cancer Research in Washington this weekend.
Pfizer Oncology announced Wednesday that the company would present data on investigational cancer drugs such as figitumumab, a monoclonal antibody for lung cancer, as well as Sutent (sunitinib) and the kidney cancer drug axitinib, as well as drugs for lymphoma and others.
“Pfizer’s data at AACR demonstrate our strategic focus on the discovery and development of novel mechanisms that align complex biology with creative clinical strategies,” Pfizer Oncology Research Unit chief scientific officer Neil Gibson said. “Our research on the mutations and pathways that are genetic drivers of the segments of disease, defined by specific ‘genetic signatures,’ is designed to help us identify patient populations that will derive the most benefit from the novel therapeutic modalities we discover and develop.”